Advances in prostate cancer in the last 10 years and a glimpse to the future
Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer
ESMO 2021: PARPi data and their role in mono/combination therapies
Radioembolisation with chemotherapy for colorectal liver metastases
ESMO 2021: Updates in hormone-sensitive prostate cancer
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC
ESMO 2021: Breast cancer roundup
Quality of life and safety in novel therapies for prostate cancer
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer
Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer
Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer
Osimertinib in EGFR-mutation positive NSCLC
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation
Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC
ESMO Interview
ESMO Interview
ESMO Interview
